More than 65 industry players across the world are presently engaged in evaluating the clinical applications of over 180 cannabinoid-derivatives that target the human endocannabinoid signalling system
Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance.
132
views

Over time, extensive R&D on the potentialhealth benefits of cannabis, have enabled medical researchers to identify anumber of pharmacologically active ingredients that offer clinical benefit,minus the addictive properties of the crude substance. Currently, severalstakeholders in the pharmaceutical industry are actively engaged in the effortsto develop leads based on natural and synthetic derivatives of cannabinoids.

 

To order this 250+ page report, which features140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html

 

The over USD 5 billion (by 2030)financial opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across thefollowing segments:

§ Target DiseaseIndication

§ Cancer

§ Genetic Disorders

§ NeurologicalIndications

§ Others

 

§ Route of Administration

§ Oral

§ Inhalation

 

§ Key Geographies

§ North America

§ Europe

Asia-Pacificand the Rest of the World

 

The“EndocannabinoidSystem Targeted Therapeutics Market, 2020-2030" report features the followingcompanies, which we identified to be key players in this domain:

§ GW Pharmaceuticals

§ Corbus Pharmaceuticals

§ Tilray

§ Tetra Bio-Pharma

§ Botanix Pharmaceuticals

§ Kalytera Therapeutics

§ Therapix Biosciences

§ Echo Pharmaceuticals

§ Avicanna

§ GB Sciences

 

Table of Contents

 

1.         PREFACE

 

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

 

4.         MARKET LANDSCAPE:ENDOCANNABINOID SYSTEM TARGETED THERAPEUTICS

 

5.         COMPANY PROFILES

 

6.         ACADEMIC GRANTS ANALYSIS

 

7.         PARTNERSHIPS ANDCOLLABORATIONS

 

8.         MERGERS AND ACQUISITIONS

 

9.         DRUG DEVELOPMENTSTRATEGY ANALYSIS

10.       MARKET FORECAST ANDOPPORTUNITY ANALYSIS

 

11.       CONCLUDING REMARKS

 

12.       EXECUTIVE INSIGHTS

 

13.       APPENDIX 1: TABULATEDDATA

 

14.      APPENDIX 2: LIST OF COMPANIES ANDORGANIZATIONS

 

To purchase a copy,please visit https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com